Circadian changes direction

By Dylan Bushell-Embling
Thursday, 12 June, 2008

Australian biotechnology firm Circadian Technologies (ASX: CIR) is restructuring and plans to evolve from a biotech incubator to a drug development company which will specialise in cancer treatments.

Circadian has appointed a product development review group, which includes both the former head of development and the former project team leader from US biotech Amgen.

The group will oversee the company's commercialisation of cancer treatment drugs based on its VEGF inhibitors, developed by subsidiary Vegenics.

Content from other channels on our network

Antimicrobial resistance in Aussie raw retail meats remains low, FSANZ survey finds

What is permissible indulgence, and what does it mean for us in 2026?

What's new on the supermarket shelves in 2026

Large-scale solar for Cargill's oilseed processing plant in NSW

foodpro 2026 now open for registrations

A matter of influence: getting over the 'ick' with recycled water

How sustainability is shaping network strategy

Upcycled mattresses to become sustainable insulation

Study finds the most effective global climate policies

UV used to make recyclable, sustainable polymers

St Vincent's Hospital Sydney junior doctors class action underway

Hospital waiting times remain high, new Productivity Commission data reveals

From vision to vigilance: building a secure digital future for health care

The Emergency Department Access & Performance Conference

REDFEB highlights the impacts of chronic stress on the heart

Circadian changes direction

argenx and Monash University partner against autoimmune diseases

Archer completes potassium sensing alpha prototype

Farm animals and aquaculture cryopreservation partnership announced

Content from other channels on our network